News and Views
Nature Medicine 14, 712 - 713 (2008)
doi:10.1038/nm0708-712
Imatinib buys time for brain after stroke
Peter Rieckmann1
-
Peter Rieckmann is in the Division of Neurology, Brain Research Centre, University of British Columbia Hospital, 2211 Wesbrook Mall, Vancouver, British Columbia V6T 2B5, Canada.
e-mail: prieckmann@brain.ubc.ca
Abstract
The most effective drug to treat acute ischemic stroke, tissue plasminogen activator (tPA), must be applied within three hours after symptom onset because of the risk of hemorrhage and other complications such as neurotoxicity. The anticancer drug imatinib (Gleevec) may help overcome these limitations by counteracting the ability of tPA to increase the permeability of the blood-brain barrier (pages 731–737).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
Free radical-mediated damage to barrier function is not associated with altered brain morphology in high-altitude headacheJournal of Cerebral Blood Flow & Metabolism Original Article
Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic strokeNature Medicine Article (01 Jul 2008)